(Q33228198)

24 July 2017

1 reference

title

Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs (English)

1 reference

24 July 2017

1 reference

Kyra A Gelderman

1

1 reference

24 July 2017

Suzanne Lam

series ordinal

2

1 reference

24 July 2017

Arko Gorter

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

Expert Opinion on Biological Therapy

24 July 2017

published in

1 reference

24 July 2017

volume

5

1 reference

24 July 2017

issue

12

1 reference

24 July 2017

page(s)

1593-1601

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Complement function in mAb-mediated cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Complement resistance of tumor cells: basal and induced mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

CD55 is over-expressed in the tumour environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Production of bi-specific monoclonal antibodies in a hollow-fibre bioreactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Recombinant approaches to IgG-like bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

CD46 is a cellular receptor for group B adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Therapeutic intervention with complement and beta-glucan in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.12.1593

10.1517/14712598.5.12.1593

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference